TG Therapeutics, Inc. (TGTX)

TG Therapeutics' stock has been influenced by several events in the past six months. The company completed enrollment in the Phase 3 ENHANCE trial for BRIUMVI and six-year data from the ULTIMATE I & II Phase 3 trials demonstrated that 89.9% of patients with relapsing multiple sclerosis were free from disability progression after continuous treatment. H.C. Wainwright initiated coverage with a "Buy" rating, and B. Riley raised its price target. Goldman Sachs upgraded the stock to a "Hold" rating. The company reported second-quarter revenue for BRIUMVI at $138.8 million, slightly exceeding guidance but aligned with expectations. The company missed its earnings estimate for the last quarter, reporting an EPS of $0.17 against a consensus of $0.32, despite a strong year-over-year revenue growth of 92.1%. TG Therapeutics completed a $100 million share repurchase program, approved a new buyback initiative, and commenced enrollment for a Phase 3 trial of a subcutaneous version of BRIUMVI. The company is projected to release its Q3 2025 earnings on October 29, 2025.

The demand for TG Therapeutics' products, specifically BRIUMVI in the multiple sclerosis market, exhibits some seasonality. The MS market tends to experience a slowdown during the summer months due to vacations. TG Therapeutics anticipated and guided for this seasonality in its Q3 2024 sales.

TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases and autoimmune diseases. Their primary approved product is BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). The company's pipeline includes TG-1701, TG-1801, and Azer-Cel, which are being developed for B-cell cancers and other diseases.

TG Therapeutics is headquartered in New York City, New York, United States. The company's operations extend to Australia and the UK. A significant portion of its revenue is generated from BRIUMVI sales in the United States.

TG Therapeutics' brand reputation has seen positive developments, driven by the success of BRIUMVI. The company secured a national contract with the Department of Veterans Affairs (VA) for BRIUMVI as the preferred anti-CD20 for relapsing forms of Multiple Sclerosis. TG Therapeutics, in collaboration with Neuraxpharm Group, launched BRIUMVI in Europe for adult patients with RMS. BRIUMVI has demonstrated strong market penetration, capturing approximately 30% of new prescriptions in the intravenous market. Consistent positive clinical trial data enhances the drug's and the company's reputation. While the company did miss its earnings estimate in the last quarter, the overall sentiment around its key product and pipeline remains positive.

TG Therapeutics is primarily owned by institutional shareholders, who hold 64.06% of the company's stock. Insiders own 49.46%, while retail investors hold 0.00% according to one source, though another indicates general public ownership at 19%. Michael S. Weiss is the largest individual shareholder, owning 23.83% of the company's shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp.